

Table S1. Cumulative CIN3+ risks from round 2 by HPV partial genotype and cytology. Invasive cervical cancers (ICC) are also shown in brackets

HPV/cytology at round 2	Follow-up from round 2 (2.5 to 4 years after entry)										
	2.5 year risk from round 2					5 year risk from round 2			10 year risk from round 2		
	n (% ¹) at round 2	n CIN3+ (ICC) ²	n CIN3+ (ICC)	%	95% CI	n CIN3+ (ICC)	%	95% CI	n CIN3+ (ICC)	%	95% CI
HR-HPV negative³	12802 (94.7%)	21 (2)	11	0.09%	(0.05%, 0.15%)	15 (1)	0.12%	(0.07%, 0.19%)	21 (2)	0.17%	(0.11%, 0.26%)
HR-HPV positive	713 (5.3%)	60 (5)	51 (2)	7.2%	(5.5%, 9.3%)	55 (3)	7.7%	(6.0%, 9.9%)	60 (5)	8.4%	(6.6%, 10.7%)
Normal cytology											
HPV16/HPV18	151 (21.2%)	12 (2)	9 (1)	6.0%	(3.2%, 11.1%)	11 (1)	7.3%	(4.1%, 12.8%)	12 (2)	8.0%	(4.6%, 13.6%)
Other HR-HPV	333 (46.7%)	10 (3)	6 (1)	1.8%	(0.8%, 4.0%)	7 (2)	2.1%	(1.0%, 4.4%)	10 (3)	3.0%	(1.6%, 5.5%)
All HR-HPV+	484 (67.9%)	22 (5)	15 (2)	3.1%	(1.9%, 5.1%)	18 (3)	3.7%	(2.4%, 5.8%)	22 (5)	4.6%	(3.0%, 6.9%)
Borderline/low-grade cytology											
HPV16/HPV18	84 (11.8%)	13	13	15.5%	(9.3%, 25.2%)	13	15.5%	(9.3%, 25.2%)	13	15.5%	(9.3%, 25.2%)
Other HR-HPV	112 (15.7%)	9	7	6.3%	(3.0%, 12.7%)	8	7.1%	(3.6%, 13.8%)	9	8.1%	(4.3%, 14.9%)
All HR-HPV+	196 (27.5%)	22	20	10.2%	(6.7%, 15.4%)	21	10.7%	(7.1%, 16.0%)	22	11.2%	(7.5%, 16.6%)
Moderate/Severe cytology											
HPV16/HPV18	20 (2.8%)	8	8	40.0%	(22.4%, 64.3%)	8	40.0%	(22.4%, 64.3%)	8	40.0%	(22.4%, 64.3%)
Other HR-HPV	13 (1.8%)	8	8	61.5%	(37.2%, 86.0%)	8	61.5%	(37.2%, 86.0%)	8	61.5%	(37.2%, 86.0%)
All HR-HPV+	33 (4.6%)	16	16	48.5%	(33.2%, 66.5%)	16	48.5%	(33.2%, 66.5%)	16	48.5%	(33.2%, 66.5%)
All women from round 2	13515 ⁴	81 (7)	62 (2)			70 (4)			81 (7)		

¹Percentages by cytology are given out of total 680 HR-HPV+ women

²In 12 to 14 years of follow-up

³HC2 negative or HC2 positive with no HR-HPV detected

⁴76 women with no cytology taken at round 2 are excluded from the table